Inflammation and the pathogenesis of diabetic nephropathy
J Wada, H Makino - Clinical science, 2013 - portlandpress.com
The most problematic issue in clinical nephrology is the relentless and progressive increase
in patients with ESRD (end-stage renal disease) worldwide. The impact of diabetic …
in patients with ESRD (end-stage renal disease) worldwide. The impact of diabetic …
Molecular mechanisms in the pathogenesis of diabetic nephropathy: an update
Diabetes mellitus is known to trigger retinopathy, neuropathy and nephropathy. Diabetic
nephropathy, a long-term major microvascular complication of uncontrolled hyperglycemia …
nephropathy, a long-term major microvascular complication of uncontrolled hyperglycemia …
Gentamicin-induced nephrotoxicity: do we have a promising therapeutic approach to blunt it?
P Balakumar, A Rohilla, A Thangathirupathi - Pharmacological research, 2010 - Elsevier
Aminoglycoside antibiotics are employed clinically because of their potent bactericidal
activities, less bacterial resistance, post-antibiotic effects and low cost. However, drugs …
activities, less bacterial resistance, post-antibiotic effects and low cost. However, drugs …
The role of peroxisome proliferator-activated receptors in kidney diseases
J Gao, Z Gu - Frontiers in Pharmacology, 2022 - frontiersin.org
Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone
receptor superfamily of ligand-activated transcription factors. Accumulating evidence …
receptor superfamily of ligand-activated transcription factors. Accumulating evidence …
Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension
J Avouac, I Konstantinova, C Guignabert… - Annals of the …, 2017 - ard.bmj.com
Objective To evaluate the antifibrotic effects of the pan-peroxisome proliferator-activated
receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and …
receptor (PPAR) agonist IVA337 in preclinical mouse models of pulmonary fibrosis and …
PPARγ as a therapeutic target in diabetic nephropathy and other renal diseases
J Yang, Y Zhou, Y Guan - Current opinion in nephrology and …, 2012 - journals.lww.com
PPARγ as a therapeutic target in diabetic nephropathy and ot... : Current Opinion in Nephrology
and Hypertension PPARγ as a therapeutic target in diabetic nephropathy and other renal …
and Hypertension PPARγ as a therapeutic target in diabetic nephropathy and other renal …
Potential antidiabetic effect of ethanolic and aqueous-ethanolic extracts of Ricinus communis leaves on streptozotocin-induced diabetes in rats
MAM Gad-Elkareem, EH Abdelgadir, OM Badawy… - PeerJ, 2019 - peerj.com
Recently, herbal drugs and their bioactive compounds have gained popularity in the
management of diabetes mellitus (DM), which has become an epidemic disease all over the …
management of diabetes mellitus (DM), which has become an epidemic disease all over the …
Protective effect of the polysaccharide from Ophiopogon japonicus on streptozotocin-induced diabetic rats
X Chen, J Tang, W Xie, J Wang, J Jin, J Ren, L Jin… - Carbohydrate …, 2013 - Elsevier
The present study was designed to investigate the effect of OJP1, a polysaccharide isolated
from the roots of Ophiopogon japonica, on blood lipid metabolism, antioxidant activity, as …
from the roots of Ophiopogon japonica, on blood lipid metabolism, antioxidant activity, as …
Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?
P Balakumar, S Kadian, N Mahadevan - Pharmacological research, 2012 - Elsevier
The uncontrolled diabetes mellitus may result in the induction of diabetic nephropathy, one
of the detrimental microvascular complications of diabetes mellitus. Diabetic nephropathy is …
of the detrimental microvascular complications of diabetes mellitus. Diabetic nephropathy is …
Interplay between statins and PPARs in improving cardiovascular outcomes: a double‐edged sword?
P Balakumar, N Mahadevan - British Journal of Pharmacology, 2012 - Wiley Online Library
Statins are best‐selling medications in the management of high cholesterol and associated
cardiovascular complications. They inhibit 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG …
cardiovascular complications. They inhibit 3‐hydroxy‐3‐methylglutaryl‐coenzyme A (HMG …